Overview

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer

Status:
Withdrawn
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and cyclophosphamide, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them at different times, may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for breast cancer. PURPOSE: Randomized phase I trial to compare the effectiveness of two regimens of docetaxel combined with doxorubicin and cyclophosphamide in treating women who have advanced breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin